Germline mutation and large deletion analysis of the CDKN2A and ARF genes in families with multiple melanoma or an aggregation of malignant melanoma and breast cancer

International Journal of Cancer

Volumn 110, Issue 4, 2004, Pages 558-562

  Dȩbniak, Tadeusz ^a,d   Górski, Bohdan ^a   Scott, Rodney J ^b   Cybulski, Cezary ^a   Mȩdrek, Krzysztof ^a   Złowocka, Elzbieta ^a   Kurzawski, Grzegorz ^a   Dȩbniak, Boguslaw ^c   Kładny, Józef ^a   Bielecka Grzela, Stanislawa ^a   Maleszka, Romuald ^a   Lubiński, Jan ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c Regional Hospital   (Poland)

^d NONE   (Poland)

Author keywords

ARF; Breast cancer; CDKN2A; Malignant melanoma; Multiplex ligation dependent probe amplification

Indexed keywords

ADULT; AGED; ARF GENE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CDKN2A GENE; FAMILY STUDY; GENE; GENE MUTATION; GENE REARRANGEMENT; GERM LINE; HUMAN; MAJOR CLINICAL STUDY; MELANOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; AGED; BREAST NEOPLASMS; GENE DELETION; GENES, P16; GERM-LINE MUTATION; HUMANS; MELANOMA; MIDDLE AGED; MULTIPLE MYELOMA; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 2442656711     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20163     Document Type: Article

References (30)

1. Goldstein AM, Tucker MA. Genetic epidemiology of familial melanoma. Dermatol Clin 1995;13:605-12.
2. Greene MH. The genetics of hereditary melanoma and nevi. 1998 update. Cancer 1999;86:2464-77.
3. Azizi E, Friedman J, Pavlotsky F, Iscovich J, Bornstein A, Shafir R, Trau H, Brenner H, Nass D. Familial cutaneous malignant melanoma and tumors of the nervous system. A hereditary cancer syndrome. Cancer 1999;76:1571-8.
4. INK4 mutations. N Engl J Med 1995;333: 970-4.
5. Kaufman DK, Kimmel DW, Parisi JE, Michels VV. A familial syndrome with cutaneous malignant melanoma and cerebral astrocytoma. Neurology 1993;43:1728-31.
6. Weston B, Grufferman S, Kostyu D, Burton CS, Grant J, et al. Familial aggregation of melanoma, basal cell carcinoma, and gastric adenocarcinoma. Cancer 1986;57:2230-4.
7. Debniak T, Gorski B, Cybulski C, Jakubowska A, Kurzawski G, Kladny J, Zaluga E, Fiedorowicz J, Debniak B, Lubinski J. Increased risk of breast cancer in relatives of malignant melanoma patients from families with strong cancer familial aggregation. Eur J Cancer Prev 2003;12:241-5.
8. Hemminki K, Lonnstedt I, Vaittinen P. A population-based study of familial cutaneous melanoma. Melanoma Res 2001;11:133-40.
9. Evans HS, Lewis CM, Robinson D, Bell CM, Moller H, Hodgson SV. Cancer risks in women with 2 breast or ovarian cancers: clues to genetic cancer susceptibility. Int J Cancer 2001;94:758-9.
10. Borg A, Sandberg T, Nilsson K, Johannsson O, Klinker M, Masback A, Westerdahl J, Olsson H, Ingvar C. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 2000;92:1260-6.
11. INK4a is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci USA 1998;95:11891-6.
12. Schneider-Stock R, Giers A, Motsch C, Boltze C, Evert M, Freigang B, Roessner A. Hereditary p16-Leiden mutation in a patient with multiple head and neck tumors. Am J Hum Genet 2003;72:216-8.
13. Whelan AJ, Bartsch D, Goodfellow PJ. Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med 1995;33:975-7.
14. Soufir N, Avril MF, Chompret A, Demenais F, Bombled J, Spatz A, Stoppa-Lyonnet D, Benard J, Bressac-de Paillerets B. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. French Familial Melanoma Study Group. Hum Mol Genet 1998;7:941.
15. ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc Natl Acad Sci USA 1996;93:8541-5.
16. Platz A, Hansson J, Ringborg U. Screening of germline mutations in the CDK4, CDKN2C and TP53 genes in familial melanoma: a clinic-based population study. Int J Cancer 1998;25:13-5.
17. Platz A, Hansson J, Mansson-Brahme E, Lagerlof B, Linder S, Lundqvist E, Sevigny P, Inganas M, Ringborg U. Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma. J Natl Cancer Inst 1997;89:697-702.
18. Lamperska K, Karezewska A, Kwiatkowska E, Mackiewicz A. Analysis of mutations in the p16/CDKN2A gene in sporadic and familial melanoma in the Polish population. Acta Biochim Pol 2002;49:369-76.
19. ARF but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum Mol Genet 2001;10:55-62.
20. Hewitt C, Lee Wu C, Evans G, Howell A, Elles RG, Jordan R, Sloan P, Read AP, Thakker N. Germline mutation of ARF in a melanoma kindred. Hum Mol Genet 2002;11:1273-9.
21. Bahuau M, Vidaud D, Jenkins RB, Bieche I, Kimmel DW, Assouline B, Smith JS, Alderete B, Cayuela JM, Harpey JP, Caille B, Vidaud M. Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors. Cancer Res 1998;58:2298-303.
22. Hogervorst FB, Nederlof PM, Gille JJ, McElgunn CJ, Grippeling M, Pruntel R, Regnerus R, van Welsem T, van Spaendonk R, Menko FH, Kluijt I, Dommering C, et al. Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Res 2003;63:1449-53.
23. Nakagawa H, Hampel H, de la Chapelle A. Identification and characterization of genomic rearrangements of MSH2 and MLH1 in Lynch syndrome (HNPCC) by novel techniques. Hum Mutat 2003;22:258.
24. 2, EDTA, storage time, and temperature on DNA yield and quality. Biochem Genet 1993;31:321-8.
25. Merlo A, Herman JG, Mao L, Lee D J, Gabrielson E, Burger PC, Baylin SB, Sidransky D. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995;7:686-92.
26. INK4a methylation and p53 mutational status. Cancer Res 2000;60:129-33.
27. Bertram CG, Gaut RM, Barrett JH, Pinney E, Whitaker L, Turner F, Bataille V, Dos Santos Silva I, Swerdlow A, Bishop DT, Newton Bishop JA. An assessment of the CDKN2A variant Ala148Thr as a nevus/melanoma susceptibility allele. J Invest Dermatol 2002; 119: 961-5.
28. Debniak T, Gorski B, Cybulski C, Jakubowska A, Kurzawski G, Lener M, Mierzejewski M, Masojc B, Medrek K, Kladny J, Zaluga E, Maleszka R, et al. Germline 657de15 mutation in the NBS1 gene in patients with malignant melanoma of the skin. Melanoma Res 2003; 13:365-70.
29. Gorski B, Debniak T, Masojc B, Mierzejewski M, Medrek K, Cybulski C, Jakubowska A, Kurzawski G, Chosia M, Scott R, Lubinski J. Germline 657de15 mutation in the NBS1 gene in breast cancer patients. Int J Cancer 2003;106:379-81.
30. Steffen J, Varon R, Thomas M, Maurer M, Stumm M, Nowakowska D. The frequency of heterozygous germline NBSI mutation 657de15 in cancer patients from Poland. Presented at International Workshop on Nijmegen Breakage Syndrome, Prague, Czech Republic, 25-28 April 2002.